A recent study indicates that patients who discontinue new slimming jabs like semaglutide or tirzepatide can put back on lost weight far faster than those who stop traditional lifestyle plans.
Published data in a prominent medical journal demonstrates that while obese individuals frequently drop substantial amounts of their body weight while undergoing treatment, the weight comes back at an average rate of nearly a kilo each month once they quit.
"People buying such drugs should be cognizant of the potential of rapid rebound weight gain when the medication is stopped," stated researcher Dr. Susan Jebb.
This pace of recovery suggests a return to starting mass within about a year and a half.
Weighing Therapies
The study, which examined dozens of trials involving thousands of participants, compared the results of the injectable medications with older methods.
Scientists note that individuals who lose weight through diet and exercise typically experience a slower creep back—perhaps 0.1 kg a month—after stopping.
Understanding the Quick Regain
Experts suggest the mode of action of the jabs is key to understanding the accelerated rebound.
The injections imitate a natural hormone called GLP-1, which controls hunger.
"Sustained high doses of GLP-1 concentrations far above than normal may cause the body to generate a reduced amount of its own natural GLP-1, and could diminish responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' results in hunger is uncontrolled, making binge eating far more likely."
An Ongoing Issue?
The NHS recommend the jabs for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
A number of clinicians contend that, considering the likelihood of relapse, the therapy might need to be life-long.
This perspective is supported by drug manufacturers, who say that the findings "emphasize the chronic character of obesity," comparing it to managing diseases like high blood pressure.
Patient Experiences
People who have stopped the jabs report a powerful resurgence of hunger.
"I experienced a trigger flipping and you become starving," said an individual.
This challenge is compounded if patients have not established sustainable lifestyle or habit modifications during therapy.
Significant Adoption
Figures indicate that millions of adults in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Use is more common among women compared to males.
- The middle-aged age group shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
Ultimately, researchers emphasize that while GLP-1 drugs are powerful agents for shedding pounds, they are not a permanent cure and lasting health benefits relies on combined lifestyle changes.
